The Court correctly identified that Myriad is not patenting a specific molecule--but rather the information contained within. It is not even a specific nucleotide sequence that is at stake--codon degeneracy and of course medically significant mutations within the BRCA gene necessitate some ambiguity in the specific of DNA sequence for the patent.
The Myriad claim has nothing to do with the
creation of BRCA cDNA. They were not the first to perform reverse transcription (and as Thomas notes, Myriad makes no method claims). Nor were they the first to synthesize the cDNA. Anybody who has ever created a cDNA library (thousands of people, both before and after Myriad) have done so. What their patent concerns is the
sequence, i.e., the information contained within the cDNA--which is 100% determined by nature.
Nowhere in nature do you find genes encoded in GATC sequences on a dioxyribose backbone with their introns removed.
The latter part of your statement belies the inherent awkwardness of the "chemical not found in nature" argument. When a researcher makes cDNA from mRNA, is the result only "not found in nature" if the original genomic DNA had introns.
So as a result should all prokaryote-derived cDNA be unpatentable? Perhaps only certain cDNA from humans are patentable (from genes with introns)?